GW Pharmaceuticals (NASDAQ: GWPH) released its preliminary fourth-quarter results for 2019 on Sunday. Sales for the quarter totaled $108 million, with $104 million of that coming from the company's popular cannabidiol (CBD)-based drug, Epidiolex.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,